<![CDATA[Depression]]> https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/depression Wed, 17 Jun 2026 04:00:09 +0000 Zend_Feed http://blogs.law.harvard.edu/tech/rss <![CDATA[Treatment Resistant Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]> https://www.leadingmarketresearch.com/treatment-resistant-depression-drugs-in-development-by-stages-target-moa

Summary

Treatment Resistant Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Treatment Resistant Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct...

$2,000.00
]]> Tue, 12 Jul 2022 14:45:37 +0000 <![CDATA[Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]> https://www.leadingmarketresearch.com/depression-drugs-in-development-by-stages-target-moa-roa-molecule-type

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Drugs In Development, 2022, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its ...

$2,500.00
]]> Fri, 17 Jun 2022 15:11:14 +0000 <![CDATA[Bipolar Depression – Pipeline Insight, 2020]]> https://www.leadingmarketresearch.com/bipolar-depression-pipeline-insight-2020 DelveInsight’s, “Bipolar Depression – Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Bipolar Depression Understanding Bipolar Depression: Overview Bipolar disorder, formerly called manic depression, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). Symptoms During the manic phase, symptoms can include: • High level of energy and activity • Irritable mood • Decreased need for sleep • Exaggerated, puffed-up self-esteem ("grandiosity") • Rapid or "pressured" speech • Rapid thoughts • Tendency to be easily distracted • Increased recklessness • False beliefs...
$2,000.00
]]> Thu, 15 Oct 2020 14:02:56 +0000 <![CDATA[Postpartum Depression – Pipeline Insight, 2020]]> https://www.leadingmarketresearch.com/postpartum-depression-pipeline-insight-2020 DelveInsight’s, “Postpartum Depression – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Postpartum Depression Understanding Postpartum Depression: Overview The birth of a baby can trigger a jumble of powerful emotions, from excitement and joy to fear and anxiety. Most new moms experience postpartum "baby blues" after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues typically begin within the first two to three days after delivery, and may last for up to two weeks. But some new moms experience a more severe, long-lasting form of depression known as postpartum depression. Rarely, an extreme mood disorder calle...
$1,500.00
]]> Thu, 15 Oct 2020 14:02:56 +0000 <![CDATA[Bipolar Depression-Market Insights, Epidemiology, and Market Forecast–2030]]> https://www.leadingmarketresearch.com/bipolar-depression-market-insights-epidemiology-and-market-forecast-203 DelveInsight’s ‘Bipolar Depression-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. The Bipolar Depression market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Bipolar Depression market size from 2017 to 2030. The Report also covers current Bipolar Depression treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2017–2030 Bipolar Depression Disease Understanding and Treatment Algorithm Bipolar Depression Overview Bipolar disorder (BD), previously ...
$6,950.00
]]> Wed, 14 Oct 2020 15:56:15 +0000 <![CDATA[Depression - Pipeline Review, H1 2020]]> https://www.leadingmarketresearch.com/depression-pipeline-review-h1-2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2020, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its comp...

$2,000.00
]]> Thu, 07 May 2020 13:39:47 +0000 <![CDATA[Depression - Pipeline Review, H2 2019]]> https://www.leadingmarketresearch.com/depression-pipeline-review-h2-2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H2 2019, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its comp...

$2,000.00
]]> Wed, 11 Dec 2019 11:13:09 +0000 <![CDATA[Depression and Anxiety Disorders Drug Development Pipeline Review, 2018]]> https://www.leadingmarketresearch.com/depression-and-anxiety-disorders-drug-development-pipeline-review-2018

Summary

This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.

PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.

OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unloc...

$3,995.00
]]> Fri, 30 Nov 2018 11:36:19 +0000 <![CDATA[Treatment Resistant Depression Global Clinical Trials Review, H2, 2018]]> https://www.leadingmarketresearch.com/treatment-resistant-depression-global-clinical-trials-review-h2-2018

Summary

GlobalData's clinical trial report, “Treatment Resistant Depression Global Clinical Trials Review, H2, 2018" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an eff...

$2,500.00
]]> Wed, 17 Oct 2018 16:06:20 +0000 <![CDATA[Depression Treatment Drugs Markets in China]]> https://www.leadingmarketresearch.com/depression-treatment-drugs-markets-in-china China's demand for Depression Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interview...
$4,000.00
]]> Wed, 09 May 2018 11:25:43 +0000 <![CDATA[Depression Treatment Drugs Industry Forecasts - China Focus]]> https://www.leadingmarketresearch.com/depression-treatment-drugs-industry-forecasts-china-focus This study focuses on China’s Depression Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minima...
$1,800.00
]]> Wed, 09 May 2018 11:25:43 +0000 <![CDATA[Depression Treatment Drugs Companies in China]]> https://www.leadingmarketresearch.com/depression-treatment-drugs-companies-in-china This study focuses on China’s Depression Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry i...
$1,800.00
]]> Wed, 09 May 2018 11:25:43 +0000 <![CDATA[Major Depressive Disorder - Current and Future Players]]> https://www.leadingmarketresearch.com/major-depressive-disorder-current-and-future-players

Summary

GlobalData has released its pharma report, “Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MDD Market. The report identifies and analyses the key companies shaping and driving the global MDD market. The report provides insight into the competitive MDD landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for MDD
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of MDD sector through market impact analysis, future market scenario and company...

$2,995.00
]]> Mon, 27 Mar 2017 20:47:39 +0000 <![CDATA[Major Depressive Disorder - US Drug Forecast and Market Assessment to 2025]]> https://www.leadingmarketresearch.com/major-depressive-disorder-us-drug-forecast-and-market-assessment-to-2025

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the fore...

$4,995.00
]]> Mon, 27 Mar 2017 20:47:39 +0000 <![CDATA[Major Depressive Disorder - 5EU Drug Forecast and Market Assessment to 2025]]> https://www.leadingmarketresearch.com/major-depressive-disorder-5eu-drug-forecast-and-market-assessment-to-2025

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the fore...

$6,995.00
]]> Mon, 27 Mar 2017 20:47:39 +0000 <![CDATA[Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025]]> https://www.leadingmarketresearch.com/major-depressive-disorder-japan-drug-forecast-and-market-assessment-to-20

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the fore...

$4,995.00
]]> Mon, 27 Mar 2017 20:47:39 +0000 <![CDATA[PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025]]> https://www.leadingmarketresearch.com/pharmapoint-major-depressive-disorder-global-drug-forecast-and-market-as

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the fore...

$10,995.00
]]> Wed, 11 Jan 2017 12:42:31 +0000 <![CDATA[Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016]]> https://www.leadingmarketresearch.com/bipolar-disorder-manic-depression-pipeline-review-h1-2016

Summary

Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/univer...

$2,000.00
]]> Fri, 17 Jun 2016 09:15:01 +0000 <![CDATA[Major Depressive Disorder - Pipeline Review, H1 2016]]> https://www.leadingmarketresearch.com/major-depressive-disorder-pipeline-review-h1-2016

Summary

Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2016’, provides an overview of the Major Depressive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries...

$2,000.00
]]> Wed, 01 Jun 2016 20:21:18 +0000 <![CDATA[Treatment Resistant Depression - Pipeline Review, H1 2016]]> https://www.leadingmarketresearch.com/treatment-resistant-depression-pipeline-review-h1-2016

Summary

Global Markets Direct’s, ‘Treatment Resistant Depression - Pipeline Review, H1 2016’, provides an overview of the Treatment Resistant Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clini...

$2,000.00
]]> Tue, 31 May 2016 09:45:03 +0000 <![CDATA[Depression - Pipeline Review, H1 2016]]> https://www.leadingmarketresearch.com/depression-pipeline-review-h1-2016

Summary

Global Markets Direct’s, ‘Depression - Pipeline Review, H1 2016’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featu...

$2,000.00
]]> Sat, 28 May 2016 18:39:51 +0000